Jens Juul Holst

Jens Juul Holst

Professor

ORCID: 0000-0001-6853-3805

Publication year:
All
81 - 90 out of 1,829Page size: 10
Sort by: Title
  1. Published

    Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression

    Wang, Q., Bailey, C. G., Ng, C., Tiffen, J., Thoeng, A., Minhas, V., Lehman, M. L., Hendy, S. C., Buchanan, G., Nelson, C. C., Rasko, J. E. J., Holst, J. & Holst, Jens Juul, 2011, In: Cancer Research. 71, 24, p. 7525-7536 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans

    Pedersen-Bjergaard, Ulrik, Thomsen, Carsten Eckhart, Høgenhaven, H., Smed, A., Kjaer, T. W., Holst, Jens Juul, Dela, Flemming, Hilsted, Linda, Frandsen, E., Pramming, S. & Thorsteinsson, B., 2008, In: Journal of the Renin-Angiotensin-Aldosterone System. 9, 1, p. 37-48 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner

    Jepsen, Sara Lind, Albrechtsen, Nicolai Jacob Wewer, Windeløv, Johanne Agerlin, Galsgaard, Katrine Douglas, Dal, Jenna Elizabeth Hunt, Farb, T. B., Kissow, Hannelouise, Pedersen, J., Deacon, Carolyn F., Martin, R. E. & Holst, Jens Juul, 2021, In: JCI insight. 6, 4, 15 p., e143228.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1

    Ahrén, B., Adner, N., Svartberg, J., Petrella, E., Holst, Jens Juul & Gutniak, M. K., Sep 2002, In: Diabetic Medicine. 19, 9, p. 790-2 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Anti-hyperglycemi effects of stevioside in type 2 diabetic subjects

    Gregersen, S., Jeppesen, P. B., Holst, Jens Juul & Hermansen, K., 2004, In: Metabolism. 53, p. 73-76

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual ß-cell function

    Kielgast, U., Holst, Jens Juul & Madsbad, Sten, May 2011, In: Diabetes. 60, 5, p. 1599-1607 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Antidiabetogenic Effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus

    Gutniak, M., Ørskov, Cathrine, Holst, Jens Juul, Ahrén, B. & Efendic, S., 1992, In: New England Journal of Medicine. 326, p. 1316-1322

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Antidiabetogenic action of cholecystokinin in type 2 diabetes

    Ahrén, B., Holst, Jens Juul & Efendic, S., 2000, In: J. Clin. Endocrinol. Metab.. 85, p. 1043-8

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Antidiabetogenic action of glucagon-like peptide- 1 related to administration relative to meal intake in subjects with type 2 diabetes

    Gutniak, M. K., Svartberg, J., Hellstrom, P. M. & Holst, Jens Juul, 2001, In: J Intern Med. 250, p. 81-87

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Antihyperglycemic effects of stevioside in type 2 diabetic subjects

    Gregersen, S., Jeppesen, P. B., Holst, Jens Juul & Hermansen, K., Jan 2004, In: Metabolism. 53, 1, p. 73-6 4 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...5 6 7 8 9 10 11 12 ...183 Next

ID: 4207